Once a day theophylline; serum concentrations

V NERMINATHAN AND S A MCKENZIE

Paediatric Chest Clinic, Oldchurch Hospital, Romford

SUMMARY Twenty four hour profiles of serum theophylline concentrations were examined in 15 asthmatic children taking a new theophylline preparation once a day. Peak concentrations occurred at a time when nocturnal wheezing is likely. Fluctuation in concentrations throughout the day was greater than with other currently available preparations, but the importance of this has yet to be determined.

Oral theophylline now has a firm place in the day to day management of childhood asthma.1 Dosage at 12 hour intervals with a slow release preparation has been shown to result in better compliance and efficiency compared with dosage every 6 hours with a rapidly absorbed preparation.2 Peak serum theophylline concentrations after morning dosage with a slow release preparation occur two to six hours later,3, 4 corresponding to the time of maximum improvement in pulmonary function.5 One study has shown that peak serum theophylline concentrations occur later, after evening dosage, perhaps due to the difference in the rate of absorption of the drug at night.6 Another study in adult volunteers7 suggests that serum theophylline concentrations may be higher before the morning than the evening dose because the half life of theophylline is slower during the night. Many asthmatic children have their most troublesome symptoms in the early hours of the morning and so theophylline preparations which result in therapeutic concentrations during this time may well be valuable in the management of nocturnal wheezing. Studies in adults8 and children9 with slow release preparations of aminophylline have suggested that this is the case.

Measurements of pulmonary function in asthmatics with acute asthma treated with intravenous aminophylline have shown that improvement is significant when the serum theophylline concentrations reach 5 μg/ml (28 μmol/l) and correlates with the logarithm of the serum theophylline concentrations between 5 and 20 μg/ml (28 and 110 μmol/l).10, 11 Because concentrations greater than 20 μg/ml (110 μmol/l) are associated with increased frequency of side effects this value has been widely accepted as the upper limit of the therapeutic range.

One of the earliest studies in children with chronic asthma, which tried to relate improvement in control to serum theophylline concentrations after oral aminophylline, suggested that those children with concentrations greater than 10 μg/ml (55 μmol/l) had fewer symptoms.12 A more recent study in ‘stable’ adult asthmatics,13 which questions the value of maximising serum theophylline concentrations, showed improvement in pulmonary function until concentrations reached approximately 13 μg/ml (72 μmol/l), but no further significant improvement at concentrations approaching 20 μg/ml (110 μmol/l). There is good evidence that control is satisfactory in many children with concentrations lower than 10 μg/ml (55 μmol/l).14 Thus a range of serum theophylline concentrations of 5 to 20 μg/ml (28 to 110 μmol/l) probably reflects the therapeutic range. To what extent fluctuation in serum theophylline concentrations affects day to day control in chronic asthmatics has yet to be defined, and it is possible that although different preparations produce different pharmacokinetic data, they may not result in differences in overall clinical efficacy.4

A new slow release theophylline preparation (Uniphyllin, Napp Laboratories, UK) has been designed to release theophylline even more slowly than currently available preparations. Preliminary studies in adults suggest that concentrations of 5 to 20 μg/ml (28 to 110 μmol/l) can be achieved for most of a 24 hour period after a single dose, and that peak concentrations occur at about 6 hours after dosage.15 The purpose of this study was to determine for what proportion of a 24 hour period serum theophylline concentrations could be maintained within the therapeutic range in a group of asthmatic children each given a single dose of Uniphyllin in the evening, and at what time peak concentrations occurred.
Patients and methods

Fifteen asthmatic children between the ages of 6 and 13 years (mean 10.1 years) were studied. All had been referred recently to the children's chest clinic because of poorly controlled symptoms and all were considered to require daily maintenance treatment. The purpose and nature of the study were explained to both the children and their parents and consent to take part was obtained. Approval for the study was given by the hospital ethical review committee.

Uniphyllin is marketed in 400 mg and 200 mg tablets. Each is scored and can be broken once. The daily dose for each child was as near as possible 15 to 20 mg/kg and was given at 8 pm. All subjects had received this dose for at least three days before the study. Each child was admitted to hospital in the early evening of the study period and an indwelling cannula, kept patent with heparinised saline, was inserted into a forearm vein. Blood for serum theophylline measurement was collected just before the dose for that day and thereafter at 2 hour intervals for the next 24 hours.

The serum theophylline concentrations were measured using an EMIT (Syva) assay.

Results

The serum theophylline concentrations for each child are presented in the Table. The mean and standard deviation of the concentrations for the group are shown in Fig. 1. Three children had peak concentrations greater than 20 μg/ml (110 μmol/l); 23, 23, and 27 μg/ml (127, 127, and 149 μmol/l). The times that peak concentrations were obtained are also shown in the Table: in 10 of the 15 children

<table>
<thead>
<tr>
<th>Time of peak concentration (hours after dosage)</th>
<th>Minimum time (hours) concentration remained &gt; 5 μg/ml</th>
</tr>
</thead>
<tbody>
<tr>
<td>0 2 4 6 8 10 12 14 16 18 20 22 24</td>
<td></td>
</tr>
</tbody>
</table>

---

**Table**  Serum theophylline concentrations (μg/ml) over a 24 hour period

<table>
<thead>
<tr>
<th>Patient No</th>
<th>Age (years)</th>
<th>Dosage (mg/kg)</th>
<th>Hours after dosage</th>
<th>Time of peak concentration (hours after dosage)</th>
<th>Minimum time (hours) concentration remained &gt; 5 μg/ml</th>
</tr>
</thead>
<tbody>
<tr>
<td>1</td>
<td>11</td>
<td>20-0</td>
<td>10-4 14-9 16-0 14-2 13-7 12-7 11-3 10-7 11-3</td>
<td>9 1 — 8 2 — 4 24</td>
<td></td>
</tr>
<tr>
<td>2</td>
<td>8</td>
<td>21-0</td>
<td>3-4 4-9 4-5 4-8 6-4 7-8 11-3 11-3 11-3</td>
<td>9-8 7-6 4-7 3-3 12-16 12 — 12</td>
<td></td>
</tr>
<tr>
<td>3</td>
<td>10</td>
<td>17-4</td>
<td>2-9 6-6 12-7 15-9 17-3 14-6 10-4 8-7 7-2</td>
<td>5-9 4-4 3-2 2-5 8 16 — 16</td>
<td></td>
</tr>
<tr>
<td>4</td>
<td>10</td>
<td>18-7</td>
<td>2-4 2-7 5-6 12-0 20-5 20-5 18-4 19-2 18-7</td>
<td>9-8 7-8 5-8 4-4 8-10 18</td>
<td></td>
</tr>
<tr>
<td>5</td>
<td>13</td>
<td>20-7</td>
<td>4-5 7-3 — 15-3 18-9 16-3 13-8 12-5 14-9</td>
<td>13-1 12-0 2-4 8 20 — 20</td>
<td></td>
</tr>
<tr>
<td>6</td>
<td>10</td>
<td>16-4</td>
<td>4-4 3-4 10-0 17-4 16-9 — 12-1 11-8 10-2</td>
<td>9-4 9-4 5-8 4-4 6 18 — 18</td>
<td></td>
</tr>
<tr>
<td>7</td>
<td>13</td>
<td>15-7</td>
<td>6-7 7-4 7-3 8-0 8-5 — 12-9 13-6 14-4</td>
<td>12-5 10-9 9-4 9-4 16 24 — 24</td>
<td></td>
</tr>
<tr>
<td>8</td>
<td>10</td>
<td>18-1</td>
<td>4-4 10-2 11-6 16-2 — — 23-0 — 15-1 12-6 8-9 6-7</td>
<td>8-14 22</td>
<td></td>
</tr>
<tr>
<td>9</td>
<td>13</td>
<td>18-1</td>
<td>3-8 18-2 21-0 23-0 — 17-7 14-8 14-1 — 7-1 7-9 3-9 4-1</td>
<td>6-8 18 — 18</td>
<td></td>
</tr>
<tr>
<td>10</td>
<td>6</td>
<td>18-4</td>
<td>6-8 11-9 17-2 16-9 — 13-3 10-8 8-0 6-6</td>
<td>4-2 3-3 2-3 1-8 4 16</td>
<td></td>
</tr>
<tr>
<td>11</td>
<td>8</td>
<td>19-1</td>
<td>2-0 8-3 12-7 12-8 — 11-5 9-9 8-1 7-1</td>
<td>6-2 4-6 3-1 2-2 6-8 16 — 16</td>
<td></td>
</tr>
<tr>
<td>12</td>
<td>6</td>
<td>18-3</td>
<td>4-0 5-6 7-6 9-8 — 9-6 9-7 8-8 8-0</td>
<td>9-3 8-0 6-3 7-7 6-8 6-8 — 22</td>
<td></td>
</tr>
<tr>
<td>13</td>
<td>11</td>
<td>15-0</td>
<td>8-1 6-1 10-7 18-6 — 19-1 15-6 14-5 12-5</td>
<td>10-8 8-9 7-5 5-7 8-10 24 — 24</td>
<td></td>
</tr>
<tr>
<td>14</td>
<td>11</td>
<td>16-4</td>
<td>5-7 4-5 9-8 17-3 — 13-4 13-8 11-8 9-8</td>
<td>7-7 4-3 3-8 2-7 6-8 16 — 16</td>
<td></td>
</tr>
<tr>
<td>15</td>
<td>12</td>
<td>15-1</td>
<td>8-6 7-5 12-3 20-7 — 27-4 20-7 18-2 17-0</td>
<td>11-0 10-9 8-8 7-1 8-10 24 — 24</td>
<td></td>
</tr>
</tbody>
</table>

Conversion—traditional units to SI: serum theophylline 1 μg/ml = 5.5 μmol/l.

---

Once a day theophylline; serum concentrations 763

**Fig. 1** Mean serum theophylline concentrations (μg/ml) over 24 hours.

Conversion—traditional units to SI: Serum theophylline 1 μg/ml = 5.5 μmol/l.

**Fig. 2** Minimum length of time over which concentrations greater than 5 μg/ml were sustained throughout a 24 hour period.

Conversion—traditional units to SI: Serum theophylline 1 μg/ml = 5.5 μmol/l.
studied these peaks occurred between 6 and 10 hours after dosage.

All children achieved concentrations greater than 5 μg/ml (28 μmol/l) for at least 12 hours (Fig. 2) and 10 of 15 for at least 18 hours. The mean difference between peak and trough concentrations was 13 μg/ml (72 μmol/l); range 5·8 to 20·3 μg/ml (32 to 112 μmol/l).

Discussion

This study has shown that serum theophylline concentrations after a single dose of 15 to 21 mg/kg of a new slow release theophylline preparation could be sustained above 5 μg/ml (28 μmol/l) for at least 18 hours in 10 of 15 asthmatic children. Three children had peak concentrations greater than 20 μg/ml (110 μmol/l); reduction of their dosage to reduce these peak concentrations would probably have resulted in their trough concentrations becoming extremely low. On the other hand, adjustment of the dosage in three other children (patients 2, 11, and 12) might well have brought their trough concentrations above 5 μg/ml (28 μmol/l) without resulting in peak concentrations exceeding 20 μg/ml (110 μmol/l). The mean difference between peak and trough concentrations over 24 hours was 13 μg/ml (72 μmol/l). Differences over 12 hour periods using other slow release preparations have been reported in three other studies as 6·2 μg/ml (34 μmol/l) and 7·9 μg/ml (43 μmol/l). 5·2 μg/ml (29 μmol/l) and 8·7 μg/ml (48 μmol/l), and 4·6 μg/ml (25 μmol/l). When differences are examined over a 24 hour period, however, using a twice daily dosage, they seem to be larger, 6·5 μg/ml (36 μmol/l) compared with 4·5 μg/ml (25 μmol/l) over 12 hours16 and 9·0 μg/ml (50 μmol/l) compared with 7·4 μg/ml (41 μmol/l). Similarly, the percentage change of peak in relation to trough concentrations is larger for this preparation.

These figures, however, should be interpreted with caution. Because of the wide interpatient variation in absorption and clearance of theophylline, the information from mean data obscures what is significant for the individual. For example the serum theophylline concentrations in patient 1 are reasonably stable throughout the day, whereas those in patients 9 and 15 show large differences in peak and trough concentrations. In addition, the absorption of slow release theophylline preparations is known to vary within patients from day to day17 18 and during the day,19 and with food in the stomach.20 Information regarding variability of absorption with and without food in the stomach and with changes in gastric emptying times, for example related to exercise, is not available for children. Clearance rates of theophylline also show intrapatient variability.20 Thus the data presented here (as with data for other theophylline preparations) for each individual as well as for the group as a whole should be regarded only as a guideline for treatment schedules.

As long as the serum theophylline concentrations do not cause toxic symptoms or appreciably exceed 20 μg/ml (110 μmol/l), what is important is whether the concentrations produced, whatever they are, control the symptoms and provide protection against bronchoconstrictor triggers. Whether the degree of fluctuation throughout the 24 hour period with the preparation used in this study results in considerably poorer day to day control than other slow release preparations given every 12 hours needs now to be examined. As with all theophylline preparations, serum theophylline concentrations should be measured throughout the day to know whether potentially toxic concentrations are being reached. Even when concentrations are judged to be within the therapeutic range, however, viral infections such as influenza may delay clearance and toxic symptoms may result.21

Peak concentrations occurred in most children 6 to 10 hours after the dosage, at a time when night time wheezing is most likely. It would seem, therefore, that this slow release theophylline preparation, given once a day in the evening, may be useful in the management of nocturnal asthma and may well be a useful adjunct to treatment with disodium cromoglycate or inhaled corticosteroids. The lower concentrations throughout the day may not be sufficient to control symptoms in some children if the drug is given alone, but in other children may afford adequate protection. This can only be determined by evaluating each child treated.

We thank Sally and George Padmore who measured the serum theophylline concentrations and without whose cooperation and assistance this study would not have been possible.

References


6 Scott PH, Tabachnik E, Macleod S, Correia J, Newth C.
Once a day theophylline; serum concentrations 765

8 Barnes P, Greening AP, Neville L, Timmers J, Poole GW. Single-dose slow-release aminophylline at night prevents nocturnal asthma. Lancet 1982;i:299-301.

Correspondence to Dr S A McKenzie, Rush Green Hospital, Romford, Essex RM7 0YA.

Received 21 February 1984
Once a day theophylline; serum concentrations.

V Nerminathan and S A McKenzie

Arch Dis Child 1984 59: 762-765
doi: 10.1136/adc.59.8.762

Updated information and services can be found at:
http://adc.bmj.com/content/59/8/762

These include:

Email alerting service
Receive free email alerts when new articles cite this article. Sign up in the box at the top right corner of the online article.

Notes

To request permissions go to:
http://group.bmj.com/group/rights-licensing/permissions

To order reprints go to:
http://journals.bmj.com/cgi/reprintform

To subscribe to BMJ go to:
http://group.bmj.com/subscribe/